Search clinical trials for: Recombinant EphB4-HSA Fusion Protein

Total 1037 results

Northwestern University
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Active, not recruiting

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Progressive Disease | Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Adenocarcinoma | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | Castration-Resistant Prostate Carcinoma Refractory to Second-Generation... and other conditions

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Recurrent Bladder Carcinoma | Bladder Cancer Stage 0 | Bladder Cancer Stage I

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC; Vasgene Therapeutics, Inc

Recruiting

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Skin Kaposi Sarcoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Stage III Renal Cell Cancer | Recurrent Bladder Carcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | ALK Gene Mutation | EGFR Gene Mutation | Metastatic Head and Neck... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; The V Foundation...

Terminated

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Prostate Cancer | Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Vasgene Therapeutics, Inc

Recruiting

A Study of sEphB4-HSA in Kaposi Sarcoma

Kaposi Sarcoma

United States
Apogenix GmbH

Completed

APG101 in Glioblastoma

Glioblastoma Multiforme

Austria, Germany
Chengdu CoenBiotech Co., Ltd
Beijing Friendship Hospital; Beijing Chest Hospital, Capital Medical University

Completed

Phase I Clinical Trial to Evaluate the Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) in Healthy Adults Aged 18-65 and Patients With Pulmonary Tuberculosis

Tuberculosis

China
Sichuan Clover Biopharmaceuticals, Inc.

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

Malignant Ascites

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
Sichuan Clover Biopharmaceuticals, Inc.

Terminated

A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis

Peritoneal Carcinomatosis

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions

Malignant Pleural Effusions

Australia
Tianjin SinoBiotech Ltd.
Peking University Cancer Hospital & Institute

Completed

Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia

Cancer | Tumor | Underdose (Unintentional)

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum; Syntonix Pharmaceuticals, Inc.

Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

United States
Zhejiang Hisun Pharmaceutical Co. Ltd.

Unknown

Efficacy and Safety Study of Anbainuo in Chinese Patients With RA/AS in the Real World

Rheumatoid Arthritis | Ankylosing Spondylitis
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Shenzhen Third People's Hospital; Wuhan Institute for Tuberculosis Control

Recruiting

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Latent Tuberculosis Infection

China
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND)

Severe Hemophilia B

United States, Italy, Belgium, Australia, Brazil, Hong Kong, India, Ireland, Japan, South Africa, United Kingdom, Netherlands, Sweden, Canada, Poland, China, France, Germany
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Severe Hemophilia B

Sweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Recruiting

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Latent Tuberculosis Infection

China
Hengenix Biotech Inc

Completed

Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects

COVID 19

United States
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
Chengdu Kanghong Biotech Co., Ltd.
University of Wisconsin, Madison

Completed

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

Neovascular Age-related Macular Degeneration

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Livzon Pharmaceutical Group Inc.
Simoon Record Pharma Information Consulting Co., Ltd.; Guangdong Center for...

Completed

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

COVID19

China
Sichuan Clover Biopharmaceuticals, Inc.

Recruiting

A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

Chemotherapy-induced Thrombocytopenia (CIT)

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization (COVID-19)

COVID-19 Pandemic

China
University of Colorado, Denver
Vasgene Therapeutics, Inc

Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Beijing VDJBio Co., LTD.

Recruiting

Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects

Health Volunteer

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (Kids B-LONG)

Hemophilia B

United States, United Kingdom, South Africa, Netherlands, Ireland, Australia
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
Tianjin SinoBiotech Ltd.

Completed

Study on Single Administration and Dose Increment of Recombinant Human Serum Albumin/Erythrocyte Fusion Protein for Injection

Healthy Subjects

China
Livzon Pharmaceutical Group Inc.

Completed

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (COVID-19)

COVID-19 Pandemic

Malaysia, Pakistan
Tianhong Li
National Cancer Institute (NCI); OncoImmune, Inc.

Terminated

CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

Advanced Malignant Solid Neoplasm

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine (Omicron)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

COVID-19 Pandemic

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China

Search clinical trials for: Recombinant EphB4-HSA Fusion Protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations